A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma. [electronic resource]
Producer: 20030404Description: 305-10 p. digitalISSN:- 0167-6997
- Adult
- Aged
- Antimetabolites, Antineoplastic -- administration & dosage
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Carcinoma, Renal Cell -- drug therapy
- Deoxycytidine -- administration & dosage
- Drug Resistance, Neoplasm
- Female
- Hematologic Diseases -- chemically induced
- Humans
- Injections, Subcutaneous
- Interferon alpha-2
- Interferon-alpha -- administration & dosage
- Kidney Neoplasms -- drug therapy
- Male
- Middle Aged
- Recombinant Proteins
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.